Molecular Characterization of Novel Astroviruses

新型星状病毒的分子表征

基本信息

  • 批准号:
    8081014
  • 负责人:
  • 金额:
    $ 19.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-06-15 至 2012-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Worldwide, gastrointestinal infections and diarrheal diseases result in significant morbidity and mortality with approximately two million deaths each year. However, current diagnostic techniques fail to determine a causal infectious agent in 30-50 percent of cases. Astroviruses (AstV) are known to cause acute gastroenteritis in humans, other mammals and avian hosts. All eight genotypes of AstV known to infect humans are phylogenetically closely related and represent a single AstV species within the Astroviridae family. Using a combination of high throughput sequencing and degenerate PCR, we detected sequences of twelve highly divergent AstV in human stool samples from different continents. Comparative analysis of complete and partial genome sequences suggest that these highly divergent AstV variants can be classified into four novel AstV species, all of which are genetically closer to animal AstV species than to the previously known human AstV species. To prevent further spread of these novel viruses and their disease in humans worldwide, it's crucial to determine their capability of infecting humans, genetic diversity, prevalence and disease association. Data generated will help design sensitive molecular reagents and provide groundwork for future research on these novel viruses. Our hypothesis is that these four novel AstV species include several divergent genotypes which are capable of infecting humans and are associated with gastroenteritis. We propose two specific aims necessary to achieve our long term goal of understanding and reducing human disease burden caused by these novel viruses. Specific aim 1 is to characterize the full range of viral genetic diversity, develop accurate diagnostic assays and determine disease association. We have accumulated a large collection of clinical and field specimens from Mexico, Unites States, Nepal, Pakistan, India, Nigeria, Tunisia and France, that will allow us to perform these studies. Since AstV can only be propagated in cell lines derived from their natural host, specific aim 2 is to define the host tropism of these novel viruses using cell culture and to develop serological assays. Cell lines from several mammalian species will be used for infection assays and to make pure virus strains. For serology, virus neutralization and luciferase immunoprecipitation system (LIPS) assays will be optimized to detect and measure anti-virus antibodies in human serum samples thereby confirming or refuting them as human viruses. The same assays will also be used to determine viral seroprevalence, because the latter will indicate the proportion of the human populations susceptible or immune to infection by these viruses and their diseases. The proposed molecular and biological characterization of these novel viruses is critical to understand their pathogenic potential and to develop methods to prevent or interrupt their transmission. PUBLIC HEALTH RELEVANCE: Molecular characterization of the novel viruses associated with acute gastroenteritis is crucial to develop sensitive and accurate diagnostic assays. Seroprevalence studies will determine the proportion of the human populations susceptible to diseases caused by these novel astroviruses. Results of this study will help to formulate strategies to interrupt transmission of these new viruses and their diseases in humans.
描述(由申请人提供):在世界范围内,胃肠道感染和腹泻疾病导致显着的发病率和死亡率,每年约有 200 万人死亡。然而,目前的诊断技术无法确定 30-50% 病例的致病传染源。已知星状病毒 (AstV) 可引起人类、其他哺乳动物和禽类宿主的急性胃肠炎。已知感染人类的​​所有八种 AstV 基因型在系统发育上都密切相关,并且代表星状病毒科中的单一 AstV 物种。通过结合高通量测序和简并 PCR,我们在来自不同大陆的人类粪便样本中检测到了 12 种高度分化的 AstV 序列。完整和部分基因组序列的比较分析表明,这些高度分化的 AstV 变体可分为四种新的 AstV 物种,所有这些变异体在遗传上更接近动物 AstV 物种,而不是先前已知的人类 AstV 物种。为了防止这些新型病毒及其疾病在全世界人类中进一步传播,确定它们感染人类的​​能力、遗传多样性、流行率和疾病关联至关重要。生成的数据将有助于设计敏感的分子试剂,并为这些新型病毒的未来研究奠定基础。我们的假设是,这四种新的 AstV 物种包含几种不同的基因型,这些基因型能够感染人类并与胃肠炎相关。我们提出了两个具体目标,以实现我们了解和减少这些新型病毒引起的人类疾病负担的长期目标。具体目标 1 是表征病毒遗传多样性的全部范围,开发准确的诊断方法并确定疾病关联。我们积累了来自墨西哥、美国、尼泊尔、巴基斯坦、印度、尼日利亚、突尼斯和法国的大量临床和现场标本,这将使我们能够进行这些研究。由于 AstV 只能在源自其天然宿主的细胞系中繁殖,因此具体目标 2 是利用细胞培养物确定这些新型病毒的宿主趋向性并开发血清学检测方法。来自几种哺乳动物物种的细胞系将用于感染测定和制备纯病毒株。对于血清学,病毒中和和荧光素酶免疫沉淀系统(LIPS)测定将被优化,以检测和测量人血清样本中的抗病毒抗体,从而确认或驳斥它们是人类病毒。相同的测定也将用于确定病毒血清流行率,因为后者将表明对这些病毒及其疾病感染敏感或免疫的人群比例。这些新型病毒的分子和生物学特征对于了解其致病潜力和开发预防或中断其传播的方法至关重要。 公共卫生相关性:与急性胃肠炎相关的新型病毒的分子特征对于开发灵敏且准确的诊断方法至关重要。血清流行率研究将确定易患这些新型星状病毒引起的疾病的人群比例。这项研究的结果将有助于制定阻止这些新病毒及其疾病在人类中传播的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Amit Kapoor其他文献

Amit Kapoor的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Amit Kapoor', 18)}}的其他基金

A sequence-independent approach for attenuating hepaciviruses
一种与序列无关的减毒肝炎病毒方法
  • 批准号:
    10598793
  • 财政年份:
    2022
  • 资助金额:
    $ 19.83万
  • 项目类别:
Infection and prevalence of a new segmented flavivirus in the United States
美国新分段黄病毒的感染和流行
  • 批准号:
    10392327
  • 财政年份:
    2021
  • 资助金额:
    $ 19.83万
  • 项目类别:
Immune correlates of protection against hepacivirus persistence.
抵抗肝炎病毒持久性的免疫相关性。
  • 批准号:
    10378496
  • 财政年份:
    2021
  • 资助金额:
    $ 19.83万
  • 项目类别:
Immune correlates of protection against hepacivirus persistence.
抵抗肝炎病毒持久性的免疫相关性。
  • 批准号:
    10594475
  • 财政年份:
    2021
  • 资助金额:
    $ 19.83万
  • 项目类别:
Host response and liver disease in a hepatitis C-like virus rat model
丙型肝炎样病毒大鼠模型中的宿主反应和肝病
  • 批准号:
    10084805
  • 财政年份:
    2018
  • 资助金额:
    $ 19.83万
  • 项目类别:
Host response and liver disease in a hepatitis C-like virus rat model
丙型肝炎样病毒大鼠模型中的宿主反应和肝病
  • 批准号:
    10328917
  • 财政年份:
    2018
  • 资助金额:
    $ 19.83万
  • 项目类别:
Novel viruses and viral dynamics in multiple transfusion recipients
多次输血受者中的新型病毒和病毒动态
  • 批准号:
    9251876
  • 财政年份:
    2016
  • 资助金额:
    $ 19.83万
  • 项目类别:
Study of rodent HCV-GBV like viruses
啮齿动物HCV-GBV样病毒的研究
  • 批准号:
    8638384
  • 财政年份:
    2014
  • 资助金额:
    $ 19.83万
  • 项目类别:
Novel viruses and viral dynamics in multiple transfusion recipients
多次输血受者中的新型病毒和病毒动态
  • 批准号:
    8697351
  • 财政年份:
    2014
  • 资助金额:
    $ 19.83万
  • 项目类别:
Study of a novel picornavirus genus associated with Acute Flaccid Paralysis
与急性弛缓性麻痹相关的新型小核糖核酸病毒属的研究
  • 批准号:
    7896237
  • 财政年份:
    2011
  • 资助金额:
    $ 19.83万
  • 项目类别:

相似国自然基金

建立新型的基因编辑小鼠生物反应器广谱表达抗肠毒素B(SEB)单克隆抗体
  • 批准号:
    31900676
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
TRAF6/mTOR双向调控巨噬细胞极化在放疗联合PD-1抗体诱导远隔效应中的作用及机制研究
  • 批准号:
    81903135
  • 批准年份:
    2019
  • 资助金额:
    20.5 万元
  • 项目类别:
    青年科学基金项目
TLR4调控系统性红斑狼疮中自身反应性B-1a细胞活化的作用及机理研究
  • 批准号:
    81901635
  • 批准年份:
    2019
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
超高效免疫磁MOFs纳米材料设计及其在动物源样品前处理中的应用研究
  • 批准号:
    31873026
  • 批准年份:
    2018
  • 资助金额:
    61.0 万元
  • 项目类别:
    面上项目
哺乳动物细胞抗体人工进化平台的研究
  • 批准号:
    31870923
  • 批准年份:
    2018
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目

相似海外基金

The developmental pathway of fetal-derived B cells
胎儿来源的 B 细胞的发育途径
  • 批准号:
    10735381
  • 财政年份:
    2023
  • 资助金额:
    $ 19.83万
  • 项目类别:
An immunodominance-based Pan-Pneumovirus vaccine for protection against RSV and hMPV
一种基于免疫优势的泛肺炎病毒疫苗,用于预防 RSV 和 hMPV
  • 批准号:
    10735979
  • 财政年份:
    2023
  • 资助金额:
    $ 19.83万
  • 项目类别:
An immunotherapeutic IgY formulation against norovirus diarrhea
一种针对诺如病毒腹泻的免疫治疗 IgY 制剂
  • 批准号:
    10693530
  • 财政年份:
    2023
  • 资助金额:
    $ 19.83万
  • 项目类别:
Protease-activated-receptor-2 antagonists for treatment of migraine pain
蛋白酶激活受体 2 拮抗剂治疗偏头痛
  • 批准号:
    10602826
  • 财政年份:
    2023
  • 资助金额:
    $ 19.83万
  • 项目类别:
Structure, function, and antigenicity of emerging henipavirus surface glycoproteins
新兴亨尼帕病毒表面糖蛋白的结构、功能和抗原性
  • 批准号:
    10567931
  • 财政年份:
    2023
  • 资助金额:
    $ 19.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了